This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investors Deserve Answers From Galena and Cytrx About Involvement in Stock Promotion Scheme

By: Adam Feuerstein | 03/14/14 - 10:54 AM EDT

Richard Pearson's expose, published yesterday on Seeking Alpha, pulls back the curtain on the shady world of paid stock touts. It's an excellent, well-researched story, mostly because of the documentation (emails and electronic signatures) Pearson obtained linking executives at Cytrx (CYTR) and Galena Biopharma (GALE) to the publication of promotional articles under assumed names and without proper financial disclosure.

You really need to read Pearson's story now, if you haven't already. The most damning part, for me, is the evidence showing Cytrx Vice President David Haen and Lauren Terrado, executive assistant to CEO Steven Kriegsman, approving and editing these promotional articles.

Pearson has emails between himself and Tom Meyer, the lead writer and recruiter for The DreamTeam Group, the marketing firm hired by Cytrx and Galena to tout their stocks all over the Internet. These emails also demonstrate quite convincingly that Cytrx and Galena executives knew about the publication of articles under fake names and weren't bothered at all by the lack of financial disclosure -- until they realized the truth was about to come to light.

Pearson submitted a dummy promotional article about Galena in early February. On Feb. 10, Meyer emails Pearson and is told that Galena is "putting a hold on all the GALE articles right now."

In his article, Pearson speculates Galena backed out because the company knew about my story on the stock-touting articles crafted by The DreamTeam Group.

Pearson is correct. I contacted Galena and The DreamTeam Group by email and phone on Feb. 10, seeking comment for the story I published on Feb. 12. Galena executives knew about my story on Feb. 10 and quickly told Meyer to put the kibosh on any new promotional articles.

Based on the evidence gathered and published by Pearson yesterday, Galena CEO Mark Ahn wasn't exactly telling shareholders the full truth when he defended the company's actions in a letter dated Feb. 14.

On the same day, Ahn was quoted in a story Oregonian reporter Nick Budnick

Ahn, Galena's CEO, said the company did not intend to mislead investors. He did not know the DreamTeam Group was not disclosing that its promotional materials were funded by Galena. In fact, he said he'd been told DreamTeam didn't write the Seeking Alpha articles. It was "an independent writer," he said.

Galena has denied all the allegations but Ahn needs to reconcile this statement with the evidence presented in Pearson's article. Galena is scheduled to announce fourth-quarter 2013 financial results next week.

A Cytrx spokesperson told me the company is "looking into [Pearson's] story and we don't have any comment at this time."

Maybe an SEC investigation will compel Galena and Cytrx to be more forthcoming? The allegations are certainly serious enough for regulators to get involved. Amidst the stock promotion, Galena insiders sold company stock worth millions of dollars and Cytrx raised $86 million in a secondary offering. Meantime, the respective value of Galena and Cytrx's stock has fallen, leaving any investor who bought into the phony promotional campaigns with significant losses.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs